You are here

  • Home
  • Archive
  • Volume 70, Issue 2
  • Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California
  1. John Gubatan1,
  2. Steven Levitte2,
  3. Akshar Patel1,
  4. Tatiana Balabanis1,
  5. Arpita Sharma1,
  6. Elaina Jones1,
  7. Bomi Lee1,
  8. Murli Manohar1,
  9. Gayathri Swaminathan1,
  10. Walter Park1,
  11. Aida Habtezion1
  1. 1 Divison of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA
  2. 2 Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
  1. Correspondence to Dr John Gubatan, Divison of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94063, USA; jgubatan{at}stanford.edu

https://doi.org/10.1136/gutjnl-2020-321772

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Zhang et al recently described ACE2 expression along the GI tract and suggests the digestive system as a potential route for COVID-19.1 ACE2 is also expressed in the pancreas2 and lipase elevations, suggestive of pancreatic involvement, have been reported among patients with COVID-19.3 A recent case report4 demonstrated that severe pancreatitis may occur in COVID-19. However, the clinical implications of these findings with regards to COVID-19 susceptibility among patients with prior pancreatitis are unclear.

    In this retrospective study, we explored the prevalence, risk factors and outcomes of COVID-19 among patients with a history of pancreatitis. Consecutive patients whose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA testing was performed at Stanford between 4 March 2020, and 14 April 2020 (Institutional Review Board (IRB) protocol 55975) and had a history of acute (K85) or chronic pancreatitis (K86) were included. We performed univariate and multivariate logistic regression to determine …

    View Full Text